Articles

Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia

Stanford University School of Medicine, CA, USA
Avera Cancer Institute, Sioux Falls, SD, USA
Sarah Cannon Cancer Institute at Research Medical Center, Kansas City, MO, USA;Kansas University Medical Center, Kansas City, KS, USA
University of Colorado School of Medicine Division of Hematology, Aurora, CO, USA
CancerCare Manitoba, Winnipeg, MB, Canada
Mount Sinai Hospital, New York, NY, USA
Queen Elizabeth II Health Sciences Center, Halifax, NS, Canada
University of Alberta Hospital (Adult Hematology Research), Edmonton, AB, Canada
Celgene Corporation, Summit, NJ, USA
Section of Bone Marrow Transplant and Leukemia, Washington University School of Medicine, St Louis, MO, USA
Celgene Corporation, Summit, NJ, USA
Celgene Corporation, Summit, NJ, USA
Celgene Corporation, Summit, NJ, USA;Imperial College London, UK
Vol. 103 No. 1 (2018): January, 2018 https://doi.org/10.3324/haematol.2017.172353